Mochida Pharmaceutical Co., Ltd.
[Mochida Pharmaceutical] Financial Results for 2026 | Sales of JPY 116.9 billion, Net Income of JPY 7.9 billion (up 39% YoY)
Mochida Pharmaceutical achieved sales of JPY 116.9 billion (up 11.2%) and net income of JPY 7.9 billion (up 39%) for the fiscal year ending March 2026. The pharmaceutical and healthcare businesses performed well, with sales forecasts of JPY 126.0 billion and net income of JPY 10.0 billion in 2027.
Key Figures
- Sales: JPY 116.9 billion (up 11.2% YoY)
- Net income: JPY 7.9 billion (up 39% YoY)
- Total assets: JPY 1,827 billion (up 22.6% YoY)
AI要約
Performance Overview
Mochida Pharmaceutical achieved sales of JPY 116.9 billion (up 11.2% YoY) and net income of JPY 7.9 billion (up 39%) for the fiscal year ending March 2026. The pharmaceutical business maintained growth driven by the expansion of new drugs and the impact of drug price revisions. The healthcare segment also performed well, with R&D expenses totaling JPY 12.157 billion, continuing proactive investments. For 2027, sales are forecasted at JPY 126.0 billion and net income at JPY 10.0 billion, projecting growth.
Future Outlook and Shareholder Returns
Mochida Pharmaceutical anticipates sales of JPY 126.0 billion (up 7.7%) and net income of JPY 10.0 billion (up 26.5%) for the fiscal year ending March 2027, accelerating efforts to penetrate existing drug markets and develop new drugs. The company plans to distribute an annual dividend of JPY 85 and actively enhance shareholder returns. Additionally, it is promoting R&D and overseas partnerships as part of its long-term growth strategy.
Mochida Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
